Japanese Journal of Radiology

, Volume 28, Issue 2, pp 101–109

Preliminary study of early response to neoadjuvant chemotherapy after the first cycle in breast cancer: comparison of 1H magnetic resonance spectroscopy with diffusion magnetic resonance imaging

Original Article

DOI: 10.1007/s11604-009-0391-7

Cite this article as:
Tozaki, M., Oyama, Y. & Fukuma, E. Jpn J Radiol (2010) 28: 101. doi:10.1007/s11604-009-0391-7

Abstract

Purpose

The aim of this study was to assess the efficacy of single-voxel 1H magnetic resonance spectroscopy (MRS) at 1.5 T to evaluate early responses to neoadjuvant chemotherapy after the first treatment in breast cancer patients and to compare it to measurements of apparent diffusion coefficient (ADC) values derived from diffusion-weighted magnetic resonance imaging (MRI).

Materials and methods

Nine patients with breast cancer who were scheduled to receive neoadjuvant chemotherapy were recruited. MR examination after the first cycle was scheduled for a few days before the administration of the second dose.

Results

Two patients were excluded from the study because their regimen was changed after the first cycle. MRS before chemotherapy demonstrated the presence of choline (Cho) at 3.22–3.23 ppm in six cases and at 3.27 ppm in one case. Diffusion-weighted MRI before chemotherapy demonstrated a localized high-signal lesion in all cases. The change of the integral value of Cho after the first cycle of chemotherapy showed a positive correlation with the change in lesion size (r = 0.91, P = 0.01), whereas no correlation was observed between the change of ADC values after the first cycle and the change in lesion size (r = 0.45, P = 0.32).

Conclusion

MRS after the first cycle may be more sensitive to diffusion-weighted MRI to predict the pathological response.

Key words

Breast cancer Proton MRS Diffusion-weighted imaging Neoadjuvant chemotherapy Therapeutic response 

Copyright information

© Japan Radiological Society 2010

Authors and Affiliations

  1. 1.Breast CenterKameda Medical CenterKamogawaJapan
  2. 2.Department of Clinical OncologyKameda Medical CenterChibaJapan

Personalised recommendations